MX2017001302A - Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk. - Google Patents
Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk.Info
- Publication number
- MX2017001302A MX2017001302A MX2017001302A MX2017001302A MX2017001302A MX 2017001302 A MX2017001302 A MX 2017001302A MX 2017001302 A MX2017001302 A MX 2017001302A MX 2017001302 A MX2017001302 A MX 2017001302A MX 2017001302 A MX2017001302 A MX 2017001302A
- Authority
- MX
- Mexico
- Prior art keywords
- dlbcl
- biomarkers
- treatment
- biomarker
- btk inhibitor
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title abstract 7
- 238000011282 treatment Methods 0.000 title abstract 3
- 229940124291 BTK inhibitor Drugs 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 206010066476 Haematological malignancy Diseases 0.000 abstract 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 2
- 102100040177 Tyrosine-protein kinase Tec Human genes 0.000 abstract 2
- 238000003491 array Methods 0.000 abstract 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102100022454 Actin, gamma-enteric smooth muscle Human genes 0.000 abstract 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 abstract 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 abstract 1
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 abstract 1
- 102100024058 Flap endonuclease GEN homolog 1 Human genes 0.000 abstract 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 abstract 1
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 abstract 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 abstract 1
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 abstract 1
- 101000678433 Homo sapiens Actin, gamma-enteric smooth muscle Proteins 0.000 abstract 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 abstract 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 abstract 1
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 abstract 1
- 101000833646 Homo sapiens Flap endonuclease GEN homolog 1 Proteins 0.000 abstract 1
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 abstract 1
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 abstract 1
- 101001032092 Homo sapiens Histone deacetylase 9 Proteins 0.000 abstract 1
- 101001045848 Homo sapiens Histone-lysine N-methyltransferase 2B Proteins 0.000 abstract 1
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 abstract 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 abstract 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 abstract 1
- 101000984620 Homo sapiens Low-density lipoprotein receptor-related protein 1B Proteins 0.000 abstract 1
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 abstract 1
- 101000923016 Homo sapiens Protein GAPT Proteins 0.000 abstract 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 abstract 1
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 abstract 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 abstract 1
- 101000795659 Homo sapiens Tuberin Proteins 0.000 abstract 1
- 102100033467 L-selectin Human genes 0.000 abstract 1
- 102100031955 Lon protease homolog, mitochondrial Human genes 0.000 abstract 1
- 102100027121 Low-density lipoprotein receptor-related protein 1B Human genes 0.000 abstract 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 abstract 1
- 101150053046 MYD88 gene Proteins 0.000 abstract 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 abstract 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 abstract 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 abstract 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 abstract 1
- 102100031494 Protein GAPT Human genes 0.000 abstract 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 abstract 1
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 abstract 1
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 abstract 1
- 102100031638 Tuberin Human genes 0.000 abstract 1
- 102100028787 Tumor necrosis factor receptor superfamily member 11A Human genes 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 108020000318 saccharopine dehydrogenase Proteins 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462032430P | 2014-08-01 | 2014-08-01 | |
| US201562119668P | 2015-02-23 | 2015-02-23 | |
| US201562127484P | 2015-03-03 | 2015-03-03 | |
| PCT/US2015/043300 WO2016019341A1 (en) | 2014-08-01 | 2015-07-31 | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017001302A true MX2017001302A (es) | 2017-10-11 |
Family
ID=55179406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001302A MX2017001302A (es) | 2014-08-01 | 2015-07-31 | Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk. |
Country Status (13)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102224153B (zh) | 2008-09-22 | 2014-04-30 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物 |
| LT3106463T (lt) | 2008-10-22 | 2018-06-25 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| PT3205654T (pt) | 2010-05-20 | 2019-04-22 | Array Biopharma Inc | Compostos macrocíclicos como inibidores de cinases trk |
| MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| WO2016071770A2 (en) * | 2014-11-05 | 2016-05-12 | Janssen Pharmaceutica Nv | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same |
| AU2015346046B2 (en) | 2014-11-16 | 2020-06-25 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| CN113546054A (zh) | 2015-04-06 | 2021-10-26 | 詹森药业有限公司 | 包含依鲁替尼的组合物 |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| SI3800189T1 (sl) | 2016-05-18 | 2023-11-30 | Loxo Oncology, Inc. | Priprava (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo (1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| AU2017375631B2 (en) * | 2016-12-12 | 2023-06-15 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| US11085039B2 (en) | 2016-12-12 | 2021-08-10 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| EP3562796B1 (en) | 2016-12-30 | 2023-04-19 | Xcella Biosciences, Inc. | Multi-stage sample recovery system |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018225072A1 (en) | 2017-06-08 | 2018-12-13 | Enlivex Therapeutics Ltd. | Therapeutic apoptotic cells for cancer therapy |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| KR20250125432A (ko) * | 2018-06-15 | 2025-08-21 | 얀센 파마슈티카 엔브이 | 이브루티닙을 포함하는 제형/조성물 |
| GB2577909B (en) * | 2018-10-10 | 2020-11-18 | Symetrica Ltd | Gamma-ray spectrum classification |
| MX2021006368A (es) * | 2018-11-30 | 2021-10-13 | Janssen Biotech Inc | Métodos para tratar el linfoma folicular. |
| CA3117813A1 (en) | 2018-12-06 | 2020-06-11 | xCella Biosciences, Inc. | Lateral loading of microcapillary arrays |
| WO2021087044A1 (en) * | 2019-10-30 | 2021-05-06 | Celgene Corporation | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
| CN116848267A (zh) * | 2021-02-03 | 2023-10-03 | 柯瑞斯公司 | 非美诺司他治疗的生物标志物 |
| US20230010803A1 (en) * | 2021-06-30 | 2023-01-12 | Janssen Pharmaceutica Nv | Treatments for diffuse large b-cell lymphoma |
| MX2023015147A (es) * | 2021-06-30 | 2024-04-01 | Janssen Pharmaceutica Nv | Inhibidores de la tirosina quinasa de bruton y métodos de su uso. |
| JP7423090B2 (ja) * | 2022-04-07 | 2024-01-29 | 学校法人藤田学園 | 不明熱患者のｂ細胞リンパ腫診断補助キットおよび情報提供方法 |
| WO2025080543A1 (en) * | 2023-10-09 | 2025-04-17 | Bristol-Myers Squibb Company | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
| JP7696987B1 (ja) | 2023-12-22 | 2025-06-23 | 東洋鋼鈑株式会社 | 遺伝子変異を検出する方法 |
| JP7698850B1 (ja) * | 2023-12-22 | 2025-06-26 | 東洋鋼鈑株式会社 | 遺伝子変異評価用キット |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX342405B (es) * | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| US20130102477A1 (en) * | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| JP6506555B2 (ja) * | 2011-10-19 | 2019-04-24 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
| AR088570A1 (es) * | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
| KR20230170108A (ko) * | 2012-06-04 | 2023-12-18 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| BR112015001690A2 (pt) * | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| BR112015014034A2 (pt) * | 2013-01-10 | 2017-07-11 | Nimbus Iris Inc | inibidores de irak e usos dos mesmos |
-
2015
- 2015-07-31 BR BR112017001677-0A patent/BR112017001677A2/pt not_active Application Discontinuation
- 2015-07-31 JP JP2017504752A patent/JP2017523188A/ja active Pending
- 2015-07-31 WO PCT/US2015/043300 patent/WO2016019341A1/en not_active Ceased
- 2015-07-31 RU RU2017106794A patent/RU2017106794A/ru not_active Application Discontinuation
- 2015-07-31 KR KR1020177005365A patent/KR20170042614A/ko not_active Withdrawn
- 2015-07-31 CN CN201580049596.7A patent/CN106714804A/zh active Pending
- 2015-07-31 AU AU2015296010A patent/AU2015296010A1/en not_active Abandoned
- 2015-07-31 EP EP15828160.0A patent/EP3185870A4/en not_active Withdrawn
- 2015-07-31 MX MX2017001302A patent/MX2017001302A/es unknown
- 2015-07-31 US US14/815,921 patent/US20160032404A1/en not_active Abandoned
- 2015-07-31 CA CA2955744A patent/CA2955744A1/en not_active Abandoned
- 2015-07-31 SG SG11201700774UA patent/SG11201700774UA/en unknown
-
2017
- 2017-01-22 IL IL250221A patent/IL250221A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016019341A1 (en) | 2016-02-04 |
| CN106714804A (zh) | 2017-05-24 |
| CA2955744A1 (en) | 2016-02-04 |
| RU2017106794A (ru) | 2018-09-03 |
| BR112017001677A2 (pt) | 2018-07-17 |
| EP3185870A4 (en) | 2018-06-20 |
| SG11201700774UA (en) | 2017-02-27 |
| JP2017523188A (ja) | 2017-08-17 |
| AU2015296010A1 (en) | 2017-02-02 |
| EP3185870A1 (en) | 2017-07-05 |
| RU2017106794A3 (cg-RX-API-DMAC7.html) | 2019-02-27 |
| KR20170042614A (ko) | 2017-04-19 |
| IL250221A0 (en) | 2017-03-30 |
| US20160032404A1 (en) | 2016-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001302A (es) | Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk. | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| WO2012106718A3 (en) | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment | |
| BR112016027222A2 (pt) | anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer | |
| TR201907389T4 (tr) | Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem. | |
| BR112018002848A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular | |
| MX2017000840A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer. | |
| MX340453B (es) | Biomarcadores para cancer de pulmon. | |
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| MX373248B (es) | Prediccion de riesgo de evento cardiovascular y usos del mismo. | |
| WO2015176066A3 (en) | Lpa-associated protein and rna expression | |
| MX363201B (es) | Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico. | |
| MX2018001697A (es) | Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores. | |
| PH12019501942A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| MX2016006125A (es) | Procedimiento, matriz y uso de los mismos. | |
| BR112017016808A2 (pt) | biomarcadores para câncer pancreático | |
| MA39776A (fr) | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf | |
| EA201992476A1 (ru) | Способы идентификации соединений | |
| EP4427804A3 (en) | Methods of diagnosing cancer | |
| BR112018008799A2 (pt) | método de prognóstico | |
| NZ722492A (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
| MX2019008911A (es) | Metodos, matrices y usos de estos. | |
| MX360479B (es) | Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs. | |
| NZ729773A (en) | Biomarkers for disease progression in melanoma | |
| BR112016019588A2 (pt) | produto de ativação de mmp-8, e, método de determinação da ativação da mmp-8 em uma amostra |